Clinical Trial Update: An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nivolumab versus placebo after surgery in bladder or upper urinary tract cancer; results completed with posted data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Upper Urinary Tract Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Various Advanced Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-12-01